Entera Bio Ltd ENTX.OQ, ENTX.O is expected to report results on May 8 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for Entera Bio Ltd is for a loss of 7 cents per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Entera Bio Ltd is $10.00, above its last closing price of $2.29.
This summary was machine generated May 6 at 11:07 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)